Search Results

NOWDiagnostics announced the appointment of Jody Douglas Berry, Ph.D. as chief scientific officer.

NOWDiagnostics (NOWDx), a developer of over-the-counter (OTC) and point-of-care (POC) diagnostics tests and first-in-class technology and platforms, today announced they have submitted a De Novo Classification Request to the U.S. Food and Drug Administration (FDA) for the company’s First to Know™ at-home syphilis test.

The University of Arkansas and NOWDiagnostics, Inc., a Springdale-based leader in innovative diagnostics testing, announced today an active partnership to study the prevalence of SARS-CoV-2 virus antibodies among University of Arkansas (U of A) students, staff and faculty.

The American Pharmacists Association Foundation (APhA Foundation) and NOWDiagnostics, Inc., a Springdale-based leader in innovative diagnostics testing, today announced that NOWDiagnostics’ ADEXUSDx® COVID-19 antibody test, a rapid-results self-contained fingerstick test,

NOWDiagnostics, Inc. announced today it is working with BARDA, the Biomedical Advanced Research and Development Authority arm of the U.S. Department of Health and Human Services, to develop a serological test for SARS-CoV-2 antibodies that can be used across a variety of health care settings—from clinics to hospital emergency ro

NOWDiagnostics, Inc. announced today that it has received Emergency Use Authorization (EUA) for its ADEXUSDx® COVID-19 antibody test for use in moderate-complex settings and at the point-of-care from the U.S. Food and Drug Administration (FDA)

Effective December 8, 2020, NOWDiagnostics, Inc. has received Conformité Européene (CE) mark approval for its ADEXUSDx® COVID-19 ‘antibody fingerstick’ Test for use across 28 countries in the European Union (EU).

NOWDiagnostics, Inc. announced today that it has received Conformité Européene (CE) mark approval for its ADEXUSDx® COVID-19 antibody test for use in moderate/complex laboratory settings across 28 countries in the European Union (EU)